Aravax Secures FDA Fast Track Designation for PVX108 in Peanut Allergy

Aravax has received Fast Track designation from the US Food and Drug Administration for PVX108, its lead investigational immunotherapy for the treatment of peanut allergy. The regulatory milestone recognizes the therapy’s potential to address a serious condition with significant unmet medical need while enabling a more efficient development and review process.

The FDA’s Fast Track program is intended to accelerate the development of promising therapies for serious or life-threatening diseases. The designation provides sponsors with more frequent interactions with the agency, eligibility for Rolling Review, and the potential for Accelerated Approval and Priority Review if regulatory requirements are met.

PVX108 Targets Immune Tolerance without Triggering Allergic Reactions

PVX108 is a next-generation peptide immunotherapy that uses proprietary synthetic peptides to retrain the immune system to tolerate peanut allergens. Unlike conventional oral immunotherapy, the treatment is intended to restore immune tolerance while minimizing treatment-induced acute allergic reactions, a major limitation of existing desensitization approaches.

Peptide-based immunotherapy selectively targets immune pathways involved in allergic disease rather than exposing patients to whole allergen proteins. This approach may improve safety while maintaining the potential to modify the underlying disease process.

Peanut allergy is one of the most common and potentially severe food allergies worldwide. Even trace exposure can trigger life-threatening anaphylaxis, leaving patients dependent on strict allergen avoidance and emergency treatment. Although approved therapies can reduce the risk of reactions after accidental exposure, there remains a need for treatments that provide durable immune tolerance with a favorable safety profile.

Phase 2 Clinical Development Continues in the US and Australia

PVX108 is currently being evaluated in ongoing Phase 2 clinical studies (NCT05621317) conducted across sites in the United States and Australia. The studies are assessing the therapy’s clinical activity and safety in individuals with peanut allergy.

While Aravax has not released efficacy data from the ongoing program, the company expects to report key Phase 2 results later in 2026. Those findings are expected to guide subsequent regulatory discussions and future clinical development.

The Fast Track designation may also facilitate earlier regulatory engagement as clinical evidence emerges; potentially streamlining later-stage development if the investigational therapy demonstrates favorable benefit-risk outcomes.

Company Highlights Regulatory Significance

Aravax Chief Executive Officer Dr. Pascal Hickey said there remains a substantial need for safer and more effective treatments for food allergy. He noted that PVX108 has the potential to provide a more convenient, disease-modifying treatment for people living with peanut allergy while reducing the risk of treatment-associated allergic reactions.

Hickey added that Fast Track designation will allow more frequent communication with the FDA throughout development, helping align future clinical and regulatory activities and potentially accelerating patient access if the therapy continues to generate positive evidence.

Path Forward

Aravax will continue enrollment and follow-up in its ongoing Phase 2 clinical program while preparing for the release of key data later this year. Positive results could support discussions with the FDA on the next stage of development and position PVX108 for expedited regulatory pathways available under the Fast Track program, including Rolling Review and potential Priority Review or Accelerated Approval if applicable.

Reference

Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy – Aravax